Teclistamab eliminates cancer markers in 77.8% of patients

A phase 2 clinical trial published in Nature Medicine has demonstrated that teclistamab can eliminate disease markers in 77.8% of patients with high-risk latent multiple myeloma (HR-SMM).

Teclistamab is a bispecific antibody designed to link T-cells to myeloma cell proteins, enhancing the immune response against the tumor. In the study, which compared the drug to a combination of lenalidomide and dexamethasone (Rd), 45 patients received teclistamab and 14 received the Rd combination. While 77.8% of the teclistamab group showed the disappearance of disease markers, none of the patients in the Rd group achieved this result.

Multiple myeloma is a blood cancer originating in plasma cells within the bone marrow. As the disease progresses, it can lead to bone weakening, kidney damage, anemia, and increased infection vulnerability. Teclistamab has previously received approval in the United States and the European Union.